Extramedullary plasmacytoma mimicking pancreatic cancer: A case report and literature review

Kim, Jae Hyung; Paik, Woo Hyun; Joo, Mee; Kim, Jung Gon; Kim, Jong Wook; Bae, Woo Kyung; Kim, Nam Hoon; Kim, Kyung-Ah; Lee, June Sung

doi:10.4103/2303-9027.190923

Cited by 4 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, for the multiple myeloma patients with onset of pancreas, there is no consensus in treatment options and the efficacy of these treatments still need to be verified. [9–16] In this case, an intensive chemotherapy regimen of V + R + DT − PACE and VRD showed a relatively good response, indicating a possible treatment approach to patients with multiple myeloma involving the pancreas further.…”

Section: Discussionmentioning

confidence: 84%

See 1 more Smart Citation

Multiple myeloma with onset of pancreas involvement

Wang¹,

Xie²,

Zhang

2019

Medicine

View full text Add to dashboard Cite

Rationale: Multiple myeloma is the second most common hematological malignancy. Extramedullary involvement is one of the indicators of poor prognosis. There is no consensus in treatment options and the efficacy. This article reports a case of multiple myeloma with onset of pancreas involvement. Amyloidosis secondary to multiple myeloma and a partial response to the chemotherapy treatment further emphasized its rarity. Patient concerns: In this article, we report a 59-year-old male patient with a chief complaint of fatigue for 8 months and upper abdominal pain for 2 months. Diagnosis: The patients were diagnosed as amyloidosis secondary to multiple myeloma with pancreatic occupying (head–neck junction area) lesion based on laboratory examination and pathology from lymph node puncture and skin biopsy. Interventions: An intensive chemotherapy treatment as bortezomib, lenalidomide, dexamethasone, cisplatin, epirubicin, cyclophosphamide, and etoposide was given. Due to intolerance, treatment regimen was further adjusted to bortezomib, lenalidomide, and dexamethasone. Outcomes: The patient was 12 months alive. After 4 cycles of chemotherapy, a partial response was achieved and abdominal magnetic resonance imaging suggested a reduced pancreatic occupying lesion. Lessons: This case demonstrates that pancreatic involvement, digestive system neoplasm, and amyloidosis-related clinical features may be the earliest manifestations of multiple myeloma. For these patients, an intensive chemotherapy regimen may be a possible treatment approach.

show abstract

Section: Discussionmentioning

confidence: 84%

“…[8] Multiple myeloma with onset of pancreas involvement was first reported in 1958 and 8 cases have been reported so far (Table 1). [9–16]…”

Section: Discussionmentioning

confidence: 99%

Multiple myeloma with onset of pancreas involvement

Wang¹,

Xie²,

Zhang

2019

Medicine

View full text Add to dashboard Cite

show abstract

Obstructive jaundice caused by pancreatic plasmacytoma secondary to multiple myeloma: A case report and literature review

Jiang

Liu

Zhu

et al. 2020

J of Digest Diseases

View full text Add to dashboard Cite

To the Editor, Multiple myeloma is the second most common malignant tumor of the hematologic system. The main pathological manifestation of multiple myeloma is the massive proliferation of clonal plasma cells in the bone marrow. 1 Approximately 5% of patients with multiple myeloma develop extramedullary plasmacytoma during the course of the disease, among which extramedullary plasmacytoma of the pancreas is rare. 2 Pancreatic plasmacytoma typically presents as a substantial mass of the pancreas that is difficult to be differentiated from other tumors, such as carcinomas, islet cell tumors, lymphomas and metastatic tumors. 3 Moreover, knowledge on the treatment of these patients has been limited so far. Here we described a case with multiple myeloma who presented with jaundice as the main manifestation and was diagnosed as having pancreatic plasmacytoma. We also reviewed the published literatures and summarized the clinical characteristics, diagnostic methods, treatment strategies and patient prognosis of multiple myeloma with involvement of the pancreas. A 49-year-old man was diagnosed with multiple myeloma (immunoglobulin G [IgG] λ type) at our hospital in 2012. He received eight cycles of systemic chemotherapy using melphalan, prednisone, vincris

show abstract